Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 9/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.33 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11939798 | 0.92 | FFAR4 (0.36) | FPR2FFAR4ALOX5APFEN1DGAT1 | |
| SCHEMBL15381647 | 0.90 | FPR2 (0.41) | FPR2FGFR1FGFR2FFAR4PTPRC | |
| SCHEMBL11939349 | 0.90 | NAAA (0.44) | FPR2FGFR1FGFR2FFAR4PTGS2 | |
| SCHEMBL11939150 | 0.90 | NAAA (0.40) | FPR2FGFR1FGFR2FFAR4PTGS2 | |
| SCHEMBL11939217 | 0.89 | FPR2 (0.36) | FPR2PTGS2PTGS1ALOX5APFEN1 | |
| SCHEMBL11938847 | 0.89 | FPR2 (0.36) | FPR2FGFR1FGFR2FFAR4PTPRC | |
| SCHEMBL11939340 | 0.89 | HPGD (0.37) | FPR2FFAR4PTGS2PTGS1CAMKK1 | |
| SCHEMBL11939049 | 0.88 | FPR2 (0.33) | FPR2FGFR1FGFR2FFAR4 | |
| SCHEMBL11939271 | 0.88 | HPGD (0.37) | FPR2FFAR4PTGS2PTGS1CAMKK1 | |
| SCHEMBL11939359 | 0.87 | NAAA (0.37) | FPR2FGFR1FGFR2FFAR4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2012-07-05 | — | — | US | disclosed |
| WO-2011033937-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120168677-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, OCIAD1, LEO1 | FPR2 804/4885FGFR1 136/4885FGFR2 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.